Trine Baur Opstad
Position: MSc, PhD
Phone: +4723016785
Email:

Project:Atherotrombotic risk markers in patients with type 2 diabetes and coronary heart disease;Special emphasis on genetic regulation.

 

Author network for Trine Baur Opstad by COREMINE medical


Publications 2016

Helseth R, Solheim S, Arnesen H, Seljeflot I, Opstad TB (2016)
The Time Course of Markers of Neutrophil Extracellular Traps in Patients Undergoing Revascularisation for Acute Myocardial Infarction or Stable Angina Pectoris
Mediators Inflamm, 2016, 2182358
PubMed 28074081

Opstad TB, Arnesen H, Pettersen A, Seljeflot I (2016)
Combined Elevated Levels of the Proinflammatory Cytokines IL-18 and IL-12 Are Associated with Clinical Events in Patients with Coronary Artery Disease: An Observational Study
Metab Syndr Relat Disord, 14 (5), 242-8
PubMed 27058587

Opstad TB, Brusletto BS, Arnesen H, Pettersen A, Seljeflot I (2016)
Cigarette smoking represses expression of cytokine IL-12 and its regulator miR-21-An observational study in patients with coronary artery disease
Immunobiology, 222 (2), 169-175
PubMed 27765464

Publications 2015

Helseth R, Opstad T, Solheim S, Lunde K, Arnesen H, Seljeflot I (2015)
The Effect of Intracoronary Stem Cell Injection on Markers of Leukocyte Activation in Acute Myocardial Infarction
Cardiol Res, 6 (1), 209-215
PubMed 28197227

Helseth R, Weiss TW, Opstad TB, Siegbahn A, Solheim S, Freynhofer MK, Huber K, Arnesen H, Seljeflot S (2015)
Associations between circulating proteins and corresponding genes expressed in coronary thrombi in patients with acute myocardial infarction
Thromb Res, 136 (6), 1240-4
PubMed 26475405

Publications 2014

Furenes EB, Opstad TB, Solheim S, Lunde K, Arnesen H, Seljeflot I (2014)
The influence of autologous bone marrow stem cell transplantation on matrix metalloproteinases in patients treated for acute ST-elevation myocardial infarction
Mediators Inflamm, 2014, 385901
PubMed 25294955

Helseth R, Seljeflot I, Opstad T, Solheim S, Freynhofer M, Arnesen H, Huber K, Weiss T (2014)
Genes expressed in coronary thrombi are associated with ischemic time in patients with acute myocardial infarction
Thromb Res, 135 (2), 329-33
PubMed 25496999

Helseth R, Solheim S, Opstad T, Hoffmann P, Arnesen H, Seljeflot I (2014)
The time profile of Pentraxin 3 in patients with acute ST-elevation myocardial infarction and stable angina pectoris undergoing percutaneous coronary intervention
Mediators Inflamm, 2014, 608414
PubMed 24737925

Opstad TB, Arnesen H, Pettersen A, Seljeflot I (2014)
The MMP-9 -1562 C/T polymorphism in the presence of metabolic syndrome increases the risk of clinical events in patients with coronary artery disease
PLoS One, 9 (9), e106816
PubMed 25191702

Publications 2013

Opstad TB, Pettersen A, Arnesen H, Seljeflot I (2013)
The co-existence of the IL-18+183 A/G and MMP-9 -1562 C/T polymorphisms is associated with clinical events in coronary artery disease patients
PLoS One, 8 (9), e74498
PubMed 24040261

Publications 2012

Bratseth V, Pettersen A, Opstad TB, Arnesen H, Seljeflot I (2012)
Markers of hypercoagulability in CAD patients. Effects of single aspirin and clopidogrel treatment
Thromb J, 10 (1), 12
PubMed 22883224

Njerve IU, Pettersen A, Opstad TB, Arnesen H, Seljeflot I (2012)
Fractalkine and its receptor (CX3CR1) in patients with stable coronary artery disease and diabetes mellitus
Metab Syndr Relat Disord, 10 (6), 400-6
PubMed 22897138

Pettersen A, Arnesen H, Opstad TB, Bratseth V, Seljeflot I (2012)
Markers of endothelial and platelet activation are associated with high on-aspirin platelet reactivity in patients with stable coronary artery disease
Thromb Res, 130 (3), 424-8
PubMed 22795340

Publications 2011

Opstad TB, Pettersen A, Arnesen H, Seljeflot I (2011)
Circulating levels of IL-18 are significantly influenced by the IL-18 +183 A/G polymorphism in coronary artery disease patients with diabetes type 2 and the metabolic syndrome: an observational study
Cardiovasc Diabetol, 10, 110
PubMed 22141572

Opstad TB, Pettersen AA, Weiss TW, Akra S, vsteb R, Arnesen H, Seljeflot I (2011)
Genetic variation, gene-expression and circulating levels of matrix metalloproteinase-9 in patients with stable coronary artery disease
Clin Chim Acta, 413 (1-2), 113-20
PubMed 21963461

Pettersen AA, Arnesen H, Opstad TB, Seljeflot I (2011)
The influence of CYP 2C19*2 polymorphism on platelet function testing during single antiplatelet treatment with clopidogrel
Thromb J, 9, 4
PubMed 21426546

Publications 2010

Opstad TB, Eilertsen AL, Hibraaten E, Skretting G, Sandset PM (2010)
Tissue factor pathway inhibitor polymorphisms in women with and without a history of venous thrombosis and the effects of postmenopausal hormone therapy
Blood Coagul Fibrinolysis, 21 (6), 516-21
PubMed 20453636

Opstad TB, Pettersen AA, Bratseth V, Arnesen H, Seljeflot I (2010)
The influence of tissue factor and tissue factor pathway inhibitor polymorphisms on thrombin generation in stable coronary artery disease
Pathophysiol Haemost Thromb, 37 (2-4), 98-103
PubMed 21555871

Opstad TB, Pettersen AA, Weiss T, Arnesen H, Seljeflot I (2010)
Gender differences of polymorphisms in the TF and TFPI genes, as related to phenotypes in patients with coronary heart disease and type-2 diabetes
Thromb J, 8, 7
PubMed 20444258

Publications 2006

Dahm A, Rosendaal FR, Andersen TO, Sandset PM (2006)
Tissue factor pathway inhibitor anticoagulant activity: risk for venous thrombosis and effect of hormonal state
Br J Haematol, 132 (3), 333-8
PubMed 16409298

Eilertsen AL, Qvigstad E, Andersen TO, Sandvik L, Sandset PM (2006)
Conventional-dose hormone therapy (HT) and tibolone, but not low-dose HT and raloxifene, increase markers of activated coagulation
Maturitas, 55 (3), 278-87
PubMed 16713143

Eilertsen AL, Sandvik L, Mowinckel MC, Andersen TO, Qvigstad E, Sandset PM (2006)
Differential effects of conventional and low dose oral hormone therapy (HT), tibolone, and raloxifene on coagulation and fibrinolysis
Thromb Res, 120 (3), 371-9
PubMed 17156824

Publications 2005

Dahm AE, Andersen TO, Rosendaal F, Sandset PM (2005)
A novel anticoagulant activity assay of tissue factor pathway inhibitor I (TFPI)
J Thromb Haemost, 3 (4), 651-8
PubMed 15842349

Eilertsen AL, Hibraaten E, Os I, Andersen TO, Sandvik L, Sandset PM (2005)
The effects of oral and transdermal hormone replacement therapy on C-reactive protein levels and other inflammatory markers in women with high risk of thrombosis
Maturitas, 52 (2), 111-8
PubMed 16186073

Publications 2001

Bendz B, Sevre K, Andersen TO, Sandset PM (2001)
Low molecular weight heparin prevents activation of coagulation in a hypobaric environment
Blood Coagul Fibrinolysis, 12 (5), 371-4
PubMed 11505080

Publications 2000

Bendz B, Andersen TO, Sandset PM (2000)
A new sensitive chromogenic substrate assay of tissue factor pathway inhibitor type 1
Thromb Res, 97 (6), 463-72
PubMed 10704656

Bendz B, Andersen TO, Sandset PM (2000)
Dose-dependent release of endogenous tissue factor pathway inhibitor by different low molecular weight heparins
Blood Coagul Fibrinolysis, 11 (4), 343-8
PubMed 10847421

Bendz B, Rostrup M, Sevre K, Andersen TO, Sandset PM (2000)
Association between acute hypobaric hypoxia and activation of coagulation in human beings
Lancet, 356 (9242), 1657-8
PubMed 11089830

Hoibraaten E, Os I, Seljeflot I, Andersen TO, Hofstad A, Sandset PM (2000)
The effects of hormone replacement therapy on hemostatic variables in women with angiographically verified coronary artery disease: results from the estrogen in women with atherosclerosis study
Thromb Res, 98 (1), 19-27
PubMed 10706930

Publications 1999

Bendz B, Hansen JB, Andersen TO, Ostergaard P, Sandset PM (1999)
Partial depletion of tissue factor pathway inhibitor during subcutaneous administration of unfractionated heparin, but not with two low molecular weight heparins
Br J Haematol, 107 (4), 756-62
PubMed 10606880

Publications 1990

Smith P, Arnesen H, Opstad T, Kierulf P (1990)
Warfarin has no negative impact on fibrinolysis
Thromb Res, 58 (6), 653-6
PubMed 2201102

Smith P, Seljeflot I, Opstad T (1990)
Withdrawal of chronic beta-adrenoceptorblockade: effects on haemodynamics, blood lipids and haemostatic variables
Eur J Clin Pharmacol, 39 (1), 81-2
PubMed 1980463

Publications 1989

Smith P, Arnesen H, Opstad T, Dahl KH, Eritsland J (1989)
Influence of highly concentrated n-3 fatty acids on serum lipids and hemostatic variables in survivors of myocardial infarction receiving either oral anticoagulants or matching placebo
Thromb Res, 53 (5), 467-74
PubMed 2660319

Publications 1988

Smith P, Arnesen H, Dahl KH, Nilsen DW, Opstad T, Andersen P (1988)
A comparative study of venous occlusion and DDAVP stimulated fibrinolysis in normolipidemic subjects
Thromb Res, 52 (6), 655-60
PubMed 3148209